Skip to main content
Publications
Dong OM, Roberts MC, Wu RR, Voils CI, Sperber N, Gavin KL, Bates J, Chanfreau-Coffinier C, Naglich M, Kelley MJ, Vassy JL, Sriram P, Heise CW, Rivas S, Ribeiro M, Chapman JG, Voora D. Evaluation of the veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program at initial test sites. Pharmacogenomics. 2021 Nov 1;22(17):1121-33. doi: 10.2217/pgs-2021-0089
Dong OM, Bates J, Chanfreau-Coffinier C, Naglich M, Kelley MJ, Meyer LJ, Icardi M, Vassy JL, Sriram P, Heise CW, Rivas S, Ribeiro M, Jacobitz R, Rozelle S, Chapman JG, Voora D. Institutional profile: veterans affairs pharmacogenomic testing for veterans (PHASER) program. Pharmacogenomics. 2021 Jan 6;22(3):2020-0173. doi: 10.2217/pgs-2020-0173
Crew KD, Silverman TB, Vanegas A, Trivedi MS, Dimond J, Mata J, Sin M, Jones T, Terry MB, Tsai W-Y, Kukafka R. Study protocol: randomized controlled trial of web-based decision support tools for high-risk women and healthcare providers to increase breast cancer chemoprevention. Contemp Clin Trials Commun. 2019 Aug 22;22(16):100433. doi: 10.1016/j.conctc.2019.10043
Vaz LE, Kleinman KP, Kawai AT, Jin R, Kassler WJ, Grant PS, Rett MD, Goldmann DA, Calderwood MS, Soumerai SB, Lee GM. Impact of Medicare's Hospital-Acquired Condition policy on infections in safety net and non-safety net hospitals. Infect Control Hosp Epidemiol. 2015 Jun;36(6):649-55. doi: 10.1017/ice.2015.38.
David SP, Niaura R, Papandonatos GD, Shadel WG, Burkholder GJ, Britt DM, Day A, Stumpff J, Hutchison K, Murphy M, Johnstone E, Griffiths SE, Walton RT. Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res. 2003 Dec 1;5(6):935-42.